Sunflower

Market position

Sunflower positions itself as a builder of one of the larger consumer sobriety brands and as the creator of the first AI sponsor for addiction, with a comparison set that includes I Am Sober, Reframe and Sober Sidekick. It frames its addressable opportunity around the roughly $30B a year Medicaid spends on substance use disorder services and over $100B spent globally each year on treatment, and cites a $153M TAM represented by its own patient waitlist. The company states it was not first to market and competes on speed and product judgment rather than capital.

Sunflower combines a consumer sobriety app with an AI sponsor available 24/7 and is building licensed clinical services (therapy and medication) underneath the same brand, targeting Medicaid reimbursement in a heavily regulated outpatient SUD category where access to insurance-covered care is limited. Internally the company states its advantage is deciding what to build faster rather than being better funded or first to market, and it emphasizes clinical oversight and evidence-based design for its AI companion.

Technology

The product combines an AI sponsor ("Sam") built on large-language-model dialogue trained to apply CBT-style techniques for craving and urge management, check-in logging and encouragement, with visual sobriety streak tracking, guided journaling, structured education courses and an anonymous community feed. The company describes clinical oversight, evidence-based recovery principles and ethical design standards in the construction of the AI companion, and characterizes its clinic as AI-native telemedicine.

Go-to-market

Consumer app distribution through the iOS App Store with a subscription funnel, content marketing via its magazine, user-generated-content creator programs (a paid remote UGC Creator role is advertised at $50/hour), and community-driven word of mouth. Clinical expansion is being marketed to existing app users, with a waitlist of patients requesting therapy or medication, and pursued through state SUD facility licensing, state Medicaid approval and county-level MCO contracts. The company has also partnered with the Tenderloin Housing Clinic to deliver real-time addiction support to high-need residents.

Individuals seeking to quit or reduce use of alcohol, nicotine, cannabis, opioids, heroin, gambling, pornography and other addictive behaviors, including a large Medicaid-insured population that cannot afford private-pay therapy or medication. The company also references clinical partners and providers managing patients between levels of care.

Geography

Headquartered in San Francisco with a remote team. Clinical operations are live in Pennsylvania and Michigan, with a stated goal of expanding to a 50-state telemedicine SUD program. UGC creator hiring is open to the US and Canada.

History

Founded in 2024, the company launched Sunflower Sober, positioned as the first AI sponsor for addiction, which grew to a reported 100 MAU in under six months. It participated in Y Combinator's Summer 2026 batch, with Garry Tan as primary partner. In late 2025 it launched a tele-therapy offering alongside the mobile app, and it subsequently launched the Sunflower Clinic of Addiction Medicine, live in Pennsylvania and Michigan. A case study describing a partnership with the Tenderloin Housing Clinic was published in March 2026.

Risks & controversies

The company itself notes that building a 50-state Medicaid-accepting outpatient SUD program requires state-level Medicaid approval, county-level MCO contracts and physical facilities in every state, describing licensing requirements as a major obstacle. Publicly reported figures for the company diverge across sources, including differing founding years, employee counts, funding totals and user counts.